Antisurvivin oligonucleotides inhibit growth and induce apoptosis in human medullary thyroid carcinoma cells

Experimental and Molecular Medicine

Volumn 38, Issue 3, 2006, Pages 230-240

  Du, Zhen Xian ^a   Zhang, Hai Yan ^a   Gao, Da Xin ^b   Wang, Hua Qin ^c   Li, Yong Jun ^a   Liu, Guo Liang ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b First Municipal Hospital of Qinhuangdao   (China)

^c KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Inhibitor of apoptosis proteins; Oligonucleotides, antisense; Survivin protein, human; Thyroid neoplasms

Indexed keywords

ACRIDINE ORANGE; ETHIDIUM BROMIDE; FORMALDEHYDE; MESSENGER RNA; OLIGONUCLEOTIDE; PARAFFIN; PROTEIN INHIBITOR; SURVIVIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER INVASION; CANCER SIZE; CANCER STAGING; CELL CYCLE; CELL VIABILITY; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; DNA DETERMINATION; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; GENE CONTROL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; METASTASIS; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; STATISTICAL ANALYSIS; THYROID MEDULLARY CARCINOMA; WESTERN BLOTTING;

EID: 33745861656     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2006.28     Document Type: Article

References (33)

1. Abd El-Hameed A. Survivin expression in colorectal adenocarcinoma using tissue microarray. J Egypt Natl Canc Inst 2005;17:42-50
2. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-21
3. Ball DW, Baylin SB, de Bustros AC. Medullary thyroid carcinoma. In Thyroid (Braverman LE, Utiger RD, eds), 2001, 930-43, Lippincott Williams & Wilkins, Philadelphia, PA
4. Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 1996;6:305-10
5. Cao C, Mu Y, Hallahan DE, Lu B. XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene 2004;23:7047-52
6. Evans DB, Fleming JB, Lee JE, Cote G, Gagel RF. The surgical treatment of medullary thyroid carcinoma. Semin Surg Oncol 1999;16:50-63
7. Fuessel S, Kueppers B, Ning S, Kotzsch M, Kraemer K, Schmidt U, Meye A, Wirth MP. Systematic in vitro evaluation of survivin directed antisense oligodeoxynucleotides in bladder cancer cells. J Urol 2004;171:2471-6
8. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M. AJCC Cancer Staging Manual, 6th Ed, 2002, Springer-Verlag, New York, NY
9. Grossman D, McNiff JM, Li F, Altieri DC. Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. Lab Invest 1999; 79:1121-6
10. Ito Y, Yoshida H, Uruno T, Nakano K, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Matsuura N, Kakudo K, Kuma K, Miyauchi A. Survivin expression is significantly linked to the de-differentiation of thyroid carcinoma. Oncol Rep 2003;10:1337-40
11. Johnson ME, Howerth EW. Survivin: a bifunctional inhibitor of apoptosis protein. Vet Pathol 2004;41:599-607
12. Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, Mitsui A, Nishiwaki T, Moriyama S, Kudo J, Fujii Y. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 2001;95:92-5
13. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998;58:5071-4
14. Kim HS, Shiraki K, Park SH. Expression of survivin in CIN and invasive squamous cell carcinoma of uterine cervix. Anticancer Res 2002;22:805-8
15. Kren L, Brazdil J, Hermanova M, Goncharuk VN, Kallakury BV, Kaur P, Ross JS. Prognostic significance of anti-apoptosis proteins survivin and bcl-2 in non-small cell lung carcinomas: a clinicopathologic study of 102 cases. Appl Immunohistochem Mol Morphol 2004;12:44-9
16. LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998;17:3247-59
17. Lee MA, Park GS, Lee HJ, Jung JH, Kang JH, Hong YS, Lee KS, Kim DG, Kim SN. Survivin expression and its clinical significance in pancreatic cancer. BMC Cancer 2005;5:127
18. Li F, Altieri DC. The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res 1999;59:3143-51
19. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;396:580-4
20. Ma X, Wang S, Zhou J, Xing H, Xu G, Wang B, Chen G, Lu YP, Ma D. Induction of apoptosis in human ovarian epithelial cancer cells by antisurvivin oligonucleotides. Oncol Rep 2005;14:275-9
21. Olie RA, Simoes-Wust AP, Baumann B, Leech SH, Fabbro D, Stahel RA, Zangemeister-Wittke U. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 2000;60:2805-9
22. Orlandi F, Caraci P, Mussa A, Saggiorato E, Pancani G, Angeli A. Treatment of medullary thyroid carcinoma: an update. Endocr Relat Cancer 2001;8:135-47
23. Petursson SR. Metastatic medullary thyroid carcinoma. Complete response to combination chemotherapy with dacarbazine and 5-fluorouracil. Cancer 1988;62:1899-903
24. Samaan NA, Schultz PN, Hickey RC. Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy. J Clin Endocrinol Metab 1988;67:801-5
25. Shinohara ET, Hallahan DE, Lu B. The use of antisense oligonucleotides in evaluating survivin as a therapeutic target for radiation sensitization in lung cancer. Biol Proced Online 2004;6:250-6
26. Shinohara ET, Gonzalez A, Massion PP, Chen H, Li M, Freyer AS, Olson SJ, Andersen JJ, Shyr Y, Carbone DP, Johnson DH, Hallahan DE, Lu B. Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. Cancer 2005;103:1685-92
27. Sugawara M, Matsuzuka F, Fukata S, Kuma K, Moatamed F, Haugen BR. Excessive survivin expression in thyroid lymphomas. Hum Pathol 2002;33:524-7
28. Takeuchi H, Morton DL, Elashoff D, Hoon DS. Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine. Int J Cancer 2005;117:1032-8
29. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, Reed JC. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998;58:5315-20
30. Vitale G, Caraglia M, Ciccarelli A, Lupoli G, Abbruzzese A, Tagliaferri P, Lupoli G. Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer 2001;91:1797-808
31. Wu LT, Averbuch SD, Ball DW, de Bustros A, Baylin SB, McGuire WP, 3rd. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer 1994;73:432-6
32. Xia C, Xu Z, Yuan X, Uematsu K, You L, Li K, Li L, McCormick F, Jablons DM. Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol Cancer Ther 2002;1:687-94
33. Zaffaroni N, Pennati M, Daidone MG. Survivin as a target for new anticancer interventions. J Cell Mol Med 2005;9:360-72